Zobrazeno 101 - 110
of 223
pro vyhledávání: ''
Autor:
Hidekazu Segawa, Masaki Nogawa, Takeshi Yuasa, Asumi Yokota, Kiyoshi Sato, Shinya Kimura, Taira Maekawa
Publikováno v:
British Journal of Cancer
Minodronic acid (YM529) is a third-generation bisphosphonate (BP) that has been shown to directly and indirectly prevent proliferation, induce apoptosis, and inhibit metastasis of various types of cancer cells. In this study, we have investigated the
Autor:
F Recchia, Paolo Carlini, L. Doni, Rodolfo Mattioli, E Barletta, Paolo Tralongo, Luca Moscetti, Bruno Massidda, Silvia Gasperoni, F. Di Costanzo, A. Iop
Publikováno v:
British Journal of Cancer
This study was performed to determine the activity of adding continuous infusion (CI) of 5-fluorouracil (5-FU) to gemcitabine (GEM) vs GEM alone in advanced pancreatic cancer (APC). In all, 94 chemo-naïve patients with APC were randomised to receive
Autor:
Sakae Okumura, Fumiyoshi Ohyanagi, Yukitoshi Satoh, Takeshi Horai, Kazuhiko Nakagawa, Makoto Nishio, Yuichi Ishikawa, Kazuto Nishio, Atsushi Horiike
Publikováno v:
British Journal of Cancer
Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR, HER1/ErbB1) tyrosine kinase, has been shown to have clinical activity against non-small-cell lung cancers (NSCLCs), especially in women nonsmokers with adenocarcinomas. The aim of
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients
Autor:
A Jonson, V J Spanswick, R. Bulusu, J Shaw, R Sehmbi, John A. Hartley, A Mayer, Ian A. Cree, Pippa Corrie
Publikováno v:
British Journal of Cancer
Gemcitabine and treosulfan are DNA-damaging agents. Preclinical studies suggest that synergism exists when melanoma cells are exposed to both drugs concurrently. We conducted a phase I trial in advanced melanoma patients to determine the optimal dose
Autor:
Anthony Maraveyas, M J Griffin, R Todd, AM Hughes, Ashraf Azzabi, M. Lind, K Fishwick, C Kelly, Alan V. Boddy, Paula Calvert, A H Calvert, ER Plummer
Publikováno v:
British Journal of Cancer
The purpose of this study was to determine activity of temozolomide combined with paclitaxel or epothilone B in vitro, and to investigate the combination of temozolomide with paclitaxel in a Phase I clinical trial. Melanoma cell lines A375P and DX3 w
Autor:
Alan V. Boddy, Christopher P.F. Redfern, Adj Pearson, M Ruiz, Gareth J. Veal, Jane L. Armstrong
Publikováno v:
British Journal of Cancer
Recent data indicate that isomerisation to all-trans retinoic acid (ATRA) is the key mechanism underlying the favourable clinical properties of 13-cis retinoic acid (13cisRA) in the treatment of neuroblastoma. Retinoic acid (RA) metabolism is thought
Autor:
O. Koriakine, P.H.M. de Mulder, G. Kaiser, Alan Horwich, B. Paluchowska, A. van Oosterom, Sophie D. Fosså, R. de Wit, Laurence Collette, L. de Prijck
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 93(11), 1209-1214. Nature Publishing Group
British Journal of Cancer, 93, 1209-14
British Journal of Cancer, 93, 11, pp. 1209-14
British Journal of Cancer, 93(11), 1209-1214. Nature Publishing Group
British Journal of Cancer, 93, 1209-14
British Journal of Cancer, 93, 11, pp. 1209-14
Item does not contain fulltext New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in interme
Autor:
Gudrun Fleischhack, Udo Bode, Roger G. Melton, Carola Hasan, Günter Henze, D Ngampolo, S. Buchen, Andreas Zoubek
Publikováno v:
British Journal of Cancer
The methotrexate (MTX) rescue agent carboxypeptidase G2 (CPDG2) rapidly hydrolyses MTX to the inactive metabolite DAMPA (4-[[2,4-diamino-6-(pteridinyl)methyl]-methylamino]-benzoic acid) and glutamate in patients with MTX-induced renal failure and del
Autor:
Brett G.M. Hughes, Justin Stebbing, S Rumbles, Mary O'Brien, D Kitchen, Peter M. Ellis, Inderbir S. Gill
Publikováno v:
British Journal of Cancer
Background: Combining bevacizumab with first-line chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC). However, identification of patients benefitting most from bevacizumab remains elusi
Publikováno v:
British Journal of Cancer
The synthetic retinoid N-(4-hydroxphenyl) retinamide (4HPR) has manifold actions, which may contribute to its chemopreventive effects on breast cancer cell growth and progression. A role for ceramide as a stress-response signal is investigated here d